Overview
- Aspect acquired rights to Novo’s stem cell–derived islet and hypoimmune cell‑engineering technologies aimed at scalable, off‑the‑shelf implants.
- Aspect will oversee development, manufacturing and commercialization, while Novo retains options to expand its role later.
- Novo will make an additional equity investment and provide research funding, and it remains eligible for milestone payments and royalties.
- Certain research, development and manufacturing functions from the United States and Denmark will be integrated into Aspect’s platform in Canada.
- The program remains preclinical with no human trials reported, and the companies did not disclose financial terms for the expanded agreement.